Euroimmun US  |  Products  |  Autoimmune  |  Rheumatology  |  Connective tissue diseases

Connective tissue diseases

Gold standard ANA detection
IFA on HEp-2/HEp-2010 substrate is considered the “gold standard” for primary ANA detection 1

Proprietary BIOCHIP technology
Allows for ANA detection on either HEp-2 or HEp-20-10 cell substrates, in a single miniature field

Unique HEp-20-10 Substrate
An increased number of mitotic cells enhances pattern interpretation and differentiation 3

Multiple testing platforms
ELISA, IFA, and EUROLINE immunoblots for flexible workflow integration

Background

Connective tissue diseases (CTDs) are rheumatic diseases characterized by damage to the body’s connective tissues, including joints, muscles, skin, and internal organs. Autoantibodies against cellular components, including anti-nuclear antibodies (ANA), are important serological markers for CTD. Euroimmun delivers solutions to support ANA detection for efficient diagnosis of several CTD including:

  • Systemic lupus erythematosus (SLE)
  • Systemic sclerosis (SSc)
  • Sjögren’s syndrome (SS)
  • Idiopathic inflammatory myopathies (Myositis)

Diagnostics

Indirect immunofluorescence assay (IFA) on HEp-2 or HEp-20-10 cells remains the gold standard for ANA detection due to its high sensitivity and ability to reveal characteristic fluorescence patterns. The international consensus on ANA patterns (ICAP, www.anapatterns.org) defines nuclear, cytoplasmic, and mitotic patterns that guide clinical interpretation. 1,2

Euroimmun’s BIOCHIP technology allows for ANA detection on either HEp-2 or HEp-20-10 cells substrates, in a single miniature field. Unique to Euroimmun, the HEp-20-10 substrate provides a higher number of mitotic cells, aiding pattern interpretation and differentiation.3

Additionally, Euroimmun provides a range of solid-phase assays, including ELISA and EUROLINE immunoblots, covering autoantibodies relevant to SLE, SSc, SS, and myositis. These assays detect antibodies such as anti-dsDNA, anti-Sm, anti-SSA/SSB, anti-Scl-70, anti-centromere, anti-Jo-1, ribosomal P, and Ro-52.

References

  1. Edward K L Chan, Carlos A von Mühlen, Marvin J Fritzler, Jan Damoiseaux, Maria Infantino, Werner Klotz, Minoru Satoh, Lucile Musset, Ignacio García-De La Torre, Orlando Gabriel Carballo, Manfred Herold, Wilson de Melo Cruvinel, Tsuneyo Mimori, Karsten Conrad, Luis E C Andrade, the ICAP Committee, The International Consensus on ANA Patterns (ICAP) in 2021—The 6th Workshop and Current Perspectives, The Journal of Applied Laboratory Medicine, Volume 7, Issue 1, January 2022, Pages 322–330, https://doi.org/10.1093/jalm/jfab140.
  2. Damoiseaux, J., von Mühlen, C.A., Garcia-De La Torre, I. et al.International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmun Highlights7, 1 (2016). https://doi.org/10.1007/s13317-016-0075-0.
  3. Rohwäder, E., Locke, M., Fraune, J., & Fechner, K. (2015). Diagnostic profile on the IFA 40: HEp-20-10 – an immunofluorescence test for reliable antinuclear antibody screening. Expert review of molecular diagnostics15(4), 451–462. https://doi.org/10.1586/14737159.2015.993612.

Connective tissue diseases products

For in vitro diagnostic use.

For a list of all the products
Euroimmun offers please visit our Product Finder

Contact our Autoimmune product team
for further details and information

2026 Euroimmun US

Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap